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Background: After the onset of HAART, some HIV-infected individuals under treatment present a exacerbated
inflammation in response to a latent or a previously treated opportunistic pathogen termed immune reconstitution
inflammatory syndrome (IRIS). Few reports of tegumentary leishmaniasis have been described in association with
IRIS. Moreover, the immunopathogenesis of IRIS in association with Leishmania is unclear.
Case presentation: The present study reports on a 29-year-old HIV-infected individual who developed mucocutaneous
leishmaniasis associated with immune reconstitution inflammatory syndrome (IRIS) five months following highly active
antiretroviral therapy (HAART). Severe lesions resulted in the partial destruction of the nasal septum, with improvement
observed 15 days after treatment with Amphotericin B and corticosteroids. The immune response of this patient was
evaluated before and after the lesions healed. IRIS was diagnosed in association with high levels of TNF-α and IL-6.
Decreased production of IFN-γ and a low IFN-γ/IL-10 ratio were also observed in response to Leishmania antigens.
After receiving anti-leishmanial treatment, the individual’s specific Th1 immune response was restored.
Conclusion: The results suggest that the production of inflammatory cytokines by unstimulated T-lymphocytes could
contribute to occurrence of leishmaniasis associated with IRIS.
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Highly active antiretroviral therapy (HAART) has signifi-
cantly benefited the majority of HIV-infected individuals.
HAART results in a decrease in the plasma HIV-viral
load and a partial recovery of CD4 + T-lymphocytes [1].
As a consequence, a sharp decrease is observed in mor-
bidity and mortality rates [2]. However, some individuals
under treatment experience clinical deterioration as a re-
sult of unregulated and rapid restoration of the immune
response; i.e., the immune reconstitution inflammatory
syndrome (IRIS). In these cases, an exacerbated inflam-
matory immune response against subclinical pathogens
or residual antigens is observed [3].* Correspondence: grassi@bahia.fiocruz.br
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unless otherwise stated.Most cases of IRIS are associated with the Mycobac-
terium avium complex, Mycobacterium tuberculosis,
cytomegalovirus or herpes zoster [4,5]. Few cases of
tegumentary leishmaniasis as a manifestation of IRIS in
patients with AIDS have been reported to date [6-8].
Furthermore, the underlying immunological mechanisms
of IRIS in association with this co-infection remain
unclear. The present report describes a case of severe
mucocutaneous leishmaniasis as a manifestation of IRIS
in an HIV-infected patient from Brazil, and evaluates
his cellular immune responses to Leishmania antigens.Materials and methods
A case of mucocutaneous leishmaniasis in association
with IRIS in an HIV-infected individual was recorded in
2009 at the Professor Edgar Santos University Hospital
(HUPES), located in Salvador, Bahia–Brazil. The HUPESis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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case report and informed written consent was obtained
from the patient. Blood samples for immunological assess-
ments were collected prior to and immediately after (the
following day) the course of Amphotericin B and cortico-
steroid treatment. Peripheral blood mononuclear cells
(PBMCs) were isolated by passage over a Ficoll-Hypaque
gradient (Amersham Biosciences, Piscataway, NJ, USA).
PBMCs were labeled with 1.5 μM of carboxyfluorescein
succinimidyl ester dye (CFSE, Molecular Probes, Eugene-
OR) and cultured for five days in the presence of either
10 μg/mL of soluble Leishmania antigen (SLA),[9] 5 μg/
mL of phytohaemagglutinin (PHA) or culture medium,.
[10] Next, PBMCs were stained with CD4+ and CD8+
monoclonal antibodies conjugated with phycoerythrin
(PE) and allophycocyanin (APC). Cell acquisition was
performed using a FACSAria Flow-Cytometer (Becton
Dickinson, CA, USA) and subsequently analyzed by
Flowjo™ software (v7.6, Tree Star, Inc. 1997–2009). The
cell division index (DI) was used to quantify the proli-
feration intensity of T-cell subsets (DI = 0.06 for CD4+
and 0.09 for CD8+ T-cells.) The frequencies of CD4+ and
CD8+ T-cells producing intracellular cytokines were quan-
tified using flow cytometry. PBMCs were cultured in the
presence of SLA, PHA or culture medium for 18 h. Heat-
inactivated human AB serum, brefeldin A and monensin
were added to all cultures in the final four hours. Next,
PBMCs were stained with anti-CD4-fluorescein isothio-
cyanate (FITC) and anti-CD8-APC, then permeabilized
with PBS-BSA-Saponin 0.2% and incubated with anti-Figure 1 A time line of clinical manifestation of a patient with mucocut
inflammatory syndrome.INF-γ-PE, anti-TNF-α-PE, and anti-IL-10-PE (Becton
Dickinson, CA, USA). Plasma cytokine levels were quanti-
fied using the BD Cytometric Bead Array (CBA) Human
Th1/Th2 Cytokine Kit II (San Jose, CA, USA).
Case presentation
The patient, a 29-year-old HIV-1-infected male, reported
being treated for pulmonary tuberculosis in 2006. In
2007, the patient’s serology for HIV tested positive. Eight
months later, the patient reported an ulcerative lesion in
his lower right limb, which was diagnosed as tegumen-
tary leishmaniasis. He subsequently received pentavalent
antimony therapy, resulting in the healing of this lesion.
In December 2008, the patient began HAART therapy
(zidovudine, lamivudine, and efavirenz). At this time, his
CD4+ T-cell count was 160 cells/mm3 and viral load was
92,479 copies/mL. In May 2009, he presented with
ulcerative lesions on his face in association with nasal
obstruction. At this point, his CD4+ T-cell count was
516 cells/mm3 with an undetectable HIV viral load. The
lesions subsequently progressed, resulting in severe in-
flammation characterized by a pronounced swelling of
the lips, nasal and mentum regions. He was admitted to
Hospital Professor Edgard Santos (HUPES) in August
2009 (Figure 1). The lesions were crusty in appearance
and a partial destruction of the patient’s upper lip and
nose was observed (Figure 2A and B). In addition, myia-
sis was observed in his necrotic lesions. Destruction of
the nasal septum was confirmed by computerized tom-
ography of the paranasal sinus cavities (Figure 2C).aneous leishmaniasis as a manifestation of immune reconstitution
Figure 2 An HIV-infected patient with mucocutaneous leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome
(IRIS). In May 2009, five months after the initiation of HAART therapy, he presented with ulcerative lesions on his face in association with nasal
obstruction. A and B: By August 2009, the lesions progressed and severe inflammation with pronounced swelling of the lips, nasal and
mentum regions are pictured. C: Computerized tomography of the paranasal sinus cavities shows partial destruction of the nasal septum
(white arrow) (August, 2009). D: Healing of lesions observed following treatment with Prednisolone and Amphotericin B (September 2009).
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lesions. Caseous necrosis was identified by a cervical
lymph node biopsy. Amastigote forms of Leishmania
spp. were found in both skin and lymph node biopsies.
The skin test for Leishmania was positive (15 mm)
and indirect ELISA for soluble L. brasiliensis antigens
was positive, while ELISA for rK39 was negative. IgG
anti-L. braziliensis levels were measured using indirect
ELISA for soluble L. braziliensis antigens. The specie
determination was further confirmed using a serial real-
time quantitative PCR assay system, as described by
Weirather, JL, 2011 [11].
The patient was then diagnosed with mucocutaneous
leishmaniasis as a manifestation of IRIS and HAART was
discontinued. He was subsequently treated with 80 mg/
day of Prednisolone and 1 mg/Kg/day of Amphotericin B
from August to September 2009. After 15 days of treat-
ment, improvement in the mucocutaneous lesions and in
the patient’s cervical lymphadenopathy was observed
(Figure 2D). After two months of hospitalization, the
lesions had completely healed and the patient was dis-
charged. HAART therapy was subsequently reintroduced.Immune response to Leishmania antigens during and
after IRIS
Prior to treatment with Amphotericin B, the patient’s
proliferative response to SLA was undetectable in both
CD4+ and CD8+ T-cell subsets (Figure 3 – white bars).
In the absence of SLA stimulus, the production of cyto-
kines (IFN-γ, TNF-α and IL-10) by both CD4+ and CD8+
T-cells were similar under both conditions. In addition,
IL-10 production was undetectable following SLA stimu-
lation in the CD4+ T-cell subset (Figure 4A). Following
leishmanial treatment, a proliferative response to SLA
was observed in both CD4+ (DI: 0.3) and CD8+ T-cell
subsets (DI: 0.2) (Figure 3 – black bars). In the absence
of SLA stimulus, IFN-γ, TNF-α and IL-10 production by
CD4+ T-cells was undetectable, and few CD8+ T-cells
were observed producing these cytokines. By contrast, in
response to SLA stimulation, a high proportion of CD4+
and CD8+ T-cells producing TNF-α and IL-10 was de-
tected (Figure 4B). Production of IFN-γ was markedly
higher in CD8+ cells in comparison with that of CD4+
T-cells. Plasmatic levels of INF-γ, TNF-α, IL-2 and IL-10
were higher at the conclusion of treatment with
Figure 3 Evaluation of CD4+ and CD8+ T-lymphocyte proliferation
in response to soluble Leishmania antigens (SLA) in a patient
with mucocutaneous leishmaniasis as manifestation of IRIS.
Blood samples were collected before (August 2009) and one day
following the conclusion of Amphotericin B and corticosteroid
treatment (September 2009). The cell division index was calculated
using Flowjo™ software. White and black bars represent the T-cell
proliferative responses to Leishmania antigens prior to and after
Amphotericin B treatment, respectively. Dashes represent the
threshold value with respect to a positive proliferative response
(above 0.06 for CD4+ T-cell and above 0.09 CD8+ T-cell subset).
Figure 4 Proportion of CD4+ and CD8+ T-cells producing intracellula
the presence of SLA. Blood samples were collected in August 2009 from
before (A) and one day after the end (B) of Amphotericin B and corticoste
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IL-10 ratio rose from 0.0 to 3.6 over the course of treat-
ment (Table 1).
Discussion
Cutaneous leishmaniasis as a manifestation of IRIS may
appearance, following the introduction of HAART and
consequent restoration of immunity, as a new disease or
as the progression of latent disease [12]. In the present
report, the patient’s lesions developed five months after
the initiation of antiretroviral therapy, concurrent with
the recovery of the number of CD4+ T-cells.
To the best of our knowledge, only two other cases of
patients infected with HIV and the clinical form of mu-
cocutaneous leishmaniasis as a manifestation of IRIS
have been described to date [6]. In both of these cases,
disseminated skin lesions (on the arms, lower limbs and
feet) and lesions in the nasal, oropharyngeal, as well as
genital mucosa were reported. Although genital lesions
have been reported in one-third of HIV/Leishmania co-
infected patients [12,13], the patient described herein
did not show genital involvement or widespread skin
lesions. His lesions were restricted to the facial area,
especially in the nasal and oropharyngeal mucosa, with
intense inflammation resulting in destruction of the
nasal septum.r IFN-γ, TNF-α and IL-10 after culturing without stimulus, and in
a patient with mucocutaneous leishmaniasis as manifestation of IRIS
roid treatment (September 2009).
Table 1 Cytokine levels in the plasma of a patient with
mucocutaneous leishmaniasis as manifestation of IRIS,
before and after Amphotericin B treatment








IFN-γ/IL-10 ratio 0.0 3.6
Data are presented in pg/mL. Cytokine levels were quantified before and one
day after the end of Amphotericin B and corticosteroid treatment.
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from mucocutaneous leishmaniasis as a manifestation of
IRIS in this patient was correlated with an unspecific
inflammatory milieu. During the course of IRIS, CD4+
and CD8+ T-lymphocytes produced very low levels of
IFN-γ and TNF-α in response to Leishmania antigens,
yet high levels of IFN-γ by both CD4+ and CD8+ T-cells
were observed in the absence of antigen stimulation.
Conversely, after the lesions healed, a specific immune
response to Leishmania antigens was reestablished and a
profound reduction in the spontaneous production of
cytokines was observed. The decreased T-cell prolifera-
tion and low antigen-induced cytokine responses ob-
served in this patient during the course of IRIS could be
more suggestive of immunosuppression to Leishmania
antigens than a hyper-responsive state. However, the fact
that the lesions appeared at the same time the patient’s
immune system demonstrated recovery (the CD4+ T
lymphocyte count was higher than 500 cells/mm3 and
HIV viral load was undetectable) is supportive of an IRIS
diagnosis. Moreover, the initial clinical presentation of
mucosal leishmaniasis, which appeared five months after
HAART initiation, progressed to an intense inflamma-
tory response with partial destruction of the nasal
septum in less than four months.
During IRIS, the patient had a positive skin test for
Leishmania, while his antigen-specific T-cell prolifera-
tion was undetectable. This discrepancy could be ex-
plained by the dynamic of immune restoration following
HAART. The restoration of antigen-specific CD4+ T-cell
responses in vitro is mostly correlated with CD4+ mem-
ory T-cell reconstitution; whereas the improvement of
delayed type hypersensitivity is associated with the sup-
pression of viraemia [14]. However, it was not possible
to quantify antigen-specific central and effector memory
CD4+ T-lymphocytes for this patient, during IRIS or
after healing of lesions. In addition, an impairment of
in vitro proliferative response to Leishmania antigenscould be linked to the activation and exhaustion of im-
mune system found during IRIS [15]. Yet, intrinsic dif-
ferences among tests for measuring cellular immune
function could explain these divergent results.
In the present case, the participation of a specific re-
sponse to Leishmania antigens with respect to the devel-
opment of skin and mucosal lesions cannot be excluded,
since a Leishmania-specific response was not evaluated
in situ. A specific recruitment of CD4+ and CD8+ T-cells
to the ulcerative lesion is described in patients with both
cutaneous and mucosal leishmaniasis [16,17]. Specific-
ally, in the mucosal lesions it is observed high number
of IFN-γ-producing cells [16]. Indeed, a decreased type-
1 immune response to Leishmania antigens in peripheral
blood is associated with intense recruitment of Leish-
mania-specific T-cells to the lesions, which is classically
found in HIV-uninfected patients with disseminated
leishmaniasis, yet cytokine production in tegumentary
lesions was observed to be similar to that found in pa-
tients with mucocutaneous and cutaneous leishmaniasis
[18]. Following healing, though CD4+ and CD8+ T-cells
persist in treated lesions, the number of circulating
antigen-specific CD4+ and CD8+ T-cells increases in per-
ipheral blood [19,20]. Thus, in this patient the absence
of proliferative response to Leishmania antigens during
IRIS might be due to sequestration of T-cells inside le-
sions. After healing, these cells were redistributed to per-
ipheral blood.
The elevated cytokine production observed in non-
stimulated cells may be a consequence of activated
memory CD4+ T-cells specific for pathogens other than
Leishmania. These cells recirculate from lymphoid or-
gans into the peripheral blood stream during the first
two months of HAART [1,21]. Moreover, the chronic ac-
tivation of the immune system by HIV itself may also
contribute to the inflammatory state observed during
the course of IRIS [22].
High levels of IL-6 and TNF-α have been previously
described in patients with other infectious diseases in as-
sociation with IRIS [23-25]. Additionally, elevated pro-
inflammatory cytokine production is considered to be a
predictor of IRIS development in HIV-infected patients
at the onset of HAART [26]. Considering the plasma
levels of TNF-α in two HIV-uninfected patients with ac-
tive mucocutaneous leishmaniasis evaluated at our la-
boratory (22 pg/mL and 13 pg/mL) [27], the levels
observed in this patient during IRIS were similar. Fol-
lowing treatment with Amphotericin B and corticoste-
roids, an increase in plasmatic IFN-γ, as well as in the
IFN-γ/IL-10 ratio, was observed in the present case,
while TNF-α remained stable. Although treatment with
corticosteroids usually decreases the production of in-
flammatory cytokines [28], a decrease in the spontan-
eous production of IFN-γ and TNF-α was observed in
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finding may be due to the fact that post-treatment cyto-
kine quantification was performed in the plasma by a
single measurement just one day following the conclu-
sion of treatment. It is possible that subsequent mea-
surements would have found decreases in TNF-α in the
plasma.
Furthermore, the nonspecific activation of the immune
system could be a consequence of an impaired regula-
tory T-cell response or a decrease in the proportion of
these cells, since IL-10 produced by Leishmania-specific
CD4+ T-lymphocytes was not detected during the course
of IRIS [8]. The proportion of regulatory T-cells (1.8%)
in our patient prior to treatment was found to be low
(data not shown). An imbalance between the effector
and regulatory responses may also play a role in the
pathogenesis of IRIS [29,30].
IRIS is characterized by an intense inflammatory reac-
tion, leading to tissue destruction concurrent with an
increase in the number of CD4+ T-cells following
HAART. No convincing evidence has been presented in
regard to whether CD4+ T-cells specific to opportunistic
pathogens are deregulated during IRIS, much less if
these cells are involved in the pathogenesis of IRIS.
Moreover, the literature contains no reports that directly
link CD4+ T-cells specific to Leishmania antigens with
clinical manifestations of leishmaniasis in association
with IRIS. However, several reports have shown a recov-
ery of CD4+ T-cells specific to Mycobacterium tubercu-
losis, Mycobacterium avium complex and Cryptococcal
neoformans in patients who developed IRIS in associ-
ation with these infections [18,29,31]. Interestingly, an-
other study found no clear association between the
recovery of M. tuberculosis-specific CD4+ T-cells and tu-
berculosis in association with IRIS [29].
It has been suggested that the absence of T-cells, such
as occurs in the course of AIDS, may lead to the
growth of intracellular pathogens inside macrophages
that never become fully activated, and thus exert no
effector function. When antigen-specific CD4+ T-cells
are restored following HAART, these cells may intensely
stimulate macrophages and possibly other innate im-
mune cells that produce large amounts of proinflam-
matory cytokines, resulting in inflammation and tissue
destruction [31].Conclusion
In summary, the results presented herein suggest that
Leishmania-associated IRIS occurred concurrently with
the production of proinflammatory cytokines by unstimu-
lated T-lymphocytes, which is supported by the absence of
a specific host immune response against Leishmania anti-
gens in the peripheral blood of this patient.Consent
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